_PRIVATE_LIMITED_377552.webp)
Dr. Cure Pharmaceuticals (India) Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 09-12-2024
- Paid Up Capital ₹ 0.30 M
as on 09-12-2024
- Company Age 15 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -34.41%
(FY 2023)
- Profit -20.80%
(FY 2023)
- Ebitda -129.27%
(FY 2023)
- Net Worth 2.50%
(FY 2023)
- Total Assets -26.57%
(FY 2023)
About Dr. Cure Pharmaceuticals (India)
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.30 M, as per Ministry of Corporate Affairs (MCA) records.
Lajwanth Kanakaraj and Kamalesh Kumar serve as directors at the Company.
- CIN/LLPIN
U24232KA2009PTC050124
- Company No.
050124
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Jun 2009
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Dr. Cure Pharmaceuticals (India)?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Lajwanth Kanakaraj  | Managing Director | 15-Jun-2009 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Kamalesh Kumar | Director | 15-Jun-2009 | Current |
Financial Performance of Dr. Cure Pharmaceuticals (India).
Dr. Cure Pharmaceuticals (India) Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 34.41% decrease. The company also saw a substantial fall in profitability, with a 20.8% decrease in profit. The company's net worth moved up by a moderate rise of 2.5%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dr. Cure Pharmaceuticals (India)?
Unlock access to Dr. Cure Pharmaceuticals (India)'s control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Dr. Cure Pharmaceuticals (India)?
Dr. Cure Pharmaceuticals (India) has a workforce of 26 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dr. Cure Pharmaceuticals (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dr. Cure Pharmaceuticals (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
